CA
NZ
UK
AU
IND
US
…
MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for MindBio Therapeutics Corp (MBIO.CN) are limited; the company is listed in Canada and identifies as a biotechnology firm focused on therapeutic development. It appears positioned in emerging neuropsychiatric and novel-therapy areas where growth may be driven by clinical data, regulatory progress and partnerships. Investors may consider potential program milestones and collaborations as long-term value drivers.
Main risk is limited disclosure and an early-stage therapeutic profile that creates high clinical and regulatory failure risk, funding/dilution needs and low liquidity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -2.81M | -0.41M | -4.29M | -7.47M |
| Net income | -2.81M | -0.41M | -4.29M | -7.47M |
| Selling general administrative | 1.90M | 0.63M | 3.22M | 2.90M |
| Reconciled depreciation | - | - | 0.00M | 0.04M |
| Operating income | -1.93M | -0.06M | -3.16M | -5.58M |
| Interest expense | 0.58M | 0.35M | 0.45M | 0.18M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.58M | -0.35M | -0.45M | -0.18M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.93M | 0.06M | 3.16M | 5.58M |
| Total other income expense net | -0.30M | -0.00M | -0.67M | -1.71M |
| Net income from continuing ops | -2.81M | -0.41M | -4.29M | -7.47M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 0.12M | 0.19M | 0.67M | 1.61M |
| Other current assets | - | - | 0.28M | 0.22M |
| Total liab | 2.56M | 5.60M | 6.09M | 5.84M |
| Total stockholder equity | -2.38M | -5.35M | -5.36M | -4.23M |
| Capital stock | 10.68M | 5.48M | 5.37M | 4.51M |
| Retained earnings | -15.29M | -12.49M | -12.38M | -8.74M |
| Cash | 0.06M | 0.14M | 0.32M | 1.31M |
| Total current liabilities | 2.56M | 5.29M | 2.93M | 1.19M |
| Net debt | 2.18M | 4.84M | 4.65M | 3.18M |
| Short long term debt | 2.24M | 4.98M | 2.16M | - |
| Total current assets | 0.12M | 0.19M | 0.67M | 1.61M |
| Short term investments | - | 0.00M | 0.01M | 0.03M |
| Long term debt | - | - | 2.82M | 4.50M |
| Accounts payable | 0.19M | 0.23M | 0.57M | 1.19M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | 0.00M | -0.03M |
| Net borrowings | -0.01M | -0.01M | -0.11M | 6.38M |
| Total cash from financing activities | 0.43M | 0.27M | 1.04M | 5.59M |
| Net income | -2.81M | -0.41M | -4.29M | -7.47M |
| Change in cash | -0.05M | -0.18M | -1.17M | 0.83M |
| Begin period cash flow | -0.02M | -0.07M | 1.31M | 0.48M |
| End period cash flow | 0.06M | 0.14M | 0.32M | 1.31M |
| Total cash from operating activities | -0.49M | -0.38M | -2.21M | -4.72M |
| Issuance of capital stock | 0.44M | 0.00M | 1.15M | 0.00M |
| Dividends paid | - | - | 0.00M | -0.79M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.60M | -0.17M | -0.29M | 0.82M |
| Stock based compensation | 0.84M | 0.00M | 1.40M | 0.00M |
| Other non cash items | 0.56M | 0.18M | 0.95M | 1.93M |
| Free cash flow | -0.49M | -0.38M | -2.21M | -4.72M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MBIO MindBio Therapeutics Corp. |
0.01 6.25% |
0.09 | - | - | 6.89 | - | 14.50 | 88.30 |
| DRUG Bright Minds Biosciences Inc |
0.06 0.19% |
32.18 | - | - | - | 13.50 | - | -0.10 |
| METX ME Therapeutics Holdings Inc. |
- -% |
1.05 | - | - | - | 72.00 | - | - |
| TELI Telescope Innovations Corp. |
- -% |
0.34 | - | - | 4.32 | 6.45 | 4.32 | -1.62 |
| DTC Defence Therapeutics Inc |
- -% |
0.31 | - | - | - | 89.80 | - | -9.99 |
MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
1055 West Georgia Street, Vancouver, BC, Canada, V6E 4N7
| Name | Title | Year Born |
|---|---|---|
| Mr. Justin Adam Hanka | Co Founder, CEO & Director | 1974 |
| Mr. John M. Dinan | Chief Financial Officer | 1958 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...